US EditionPublished • loading... • Updated
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
Astellas will share Phase 2 results for zolbetuximab and new Phase 1 data for ASP3082 targeting KRAS G12D mutations in gastrointestinal cancers at ASCO GI 2026.
- On January 8, 2026, Astellas Pharma Inc. will present Phase 2 ILUSTRO cohort results and Phase 1 ASP3082 data at ASCO Gastrointestinal Cancers Symposium, San Francisco, California.
- Astellas is advancing CLDN18.2 targets because in SPOTLIGHT and GLOW Phase 3 trials about 38% of patients had CLDN18.2-positive tumors, supported by Ventana CLDN18 and RXDX assays.
- Safety data indicate high rates of nausea and vomiting for VYLOY combinations, with 82% in mFOLFOX6 and 69% in CAPOX; SPOTLIGHT reported 45% serious adverse reactions and 20% discontinuations.
- Regulatory uncertainty remains because the safety and efficacy of investigational agents ASP3082 and ASP4396 have not been established, and ClinicalTrials.gov identifiers NCT06901531, NCT05382559, NCT06364696 provide trial details.
- Astellas is positioning its KRAS G12D program by advancing ASP4396 and ASP3082 , targeting a mutation present in approximately 40% of pancreatic ductal adenocarcinomas.
Insights by Ground AI
21 Articles
21 Articles
Coverage Details
Total News Sources21
Leaning Left1Leaning Right0Center10Last UpdatedBias Distribution91% Center
Bias Distribution
- 91% of the sources are Center
91% Center
C 91%
Factuality
To view factuality data please Upgrade to Premium
